3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Multiple Endocrine Neoplasia Type 1
1
Emergencies
1
Interventions
Everolimus
25
Magnetic Resonance Spectroscopy
13
pembrolizumab
12
pasireotide
12
Sunitinib
11
Octreotide
11
lanreotide
10
cabozantinib
10
lenvatinib
8
Sorafenib
8
Cisplatin
8
Temozolomide
7
Etoposide
7
Bevacizumab
7
pazopanib
6
Paclitaxel
6
Nivolumab
6
Doxorubicin
6
Carboplatin
6
Capecitabine
6
vandetanib
5
gallium Ga 68 dotatate
5
Specimen Handling
5
trametinib
4
lutetium Lu 177 dotatate
4
dabrafenib
4
Mitotane
4
Iodine-131
4
telotristat ethyl
3
surufatinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Ketorolac
×
Endocrine
×
Clear all
NCT01471639
2025-08-15
Sprix
The Cleveland Clinic
Phase NA
Completed
37 enrolled
7 charts